References
- Geall MG, Schoenfield LJ, Summerskill WHJ. Classification and treatment of chronic active liver disease. Gastroenterology 1972;63:458.
- Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in acute chronic hepatitis. Q J Med 1971;40:159.
- Czaja AJ. Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis 1984;4:1.
- Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol 1995;90:1206.
- Orth T, Gerken G, Kellner R, Meyer zum Buschenfelde KH, Mayet W. Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1. J Hepatol 1997;26: 37.
- Mulder AHL, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CGM. Prevalence and characterization of neutrophic cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993;17:411.
- McFarlane IG, Hegarty JE, McSorely CG, et al. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic hepatitis. Lancet 1984;2:954.
- Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105:1824.
- Johnson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatology 1993;18:998.
- Newton IL, Burt AD, Park JB, Matthew J, Bassendine MF, James OFW. Is the new international diagnostic scoring system for autoimmune hepatitis too rigid? Hepatology 1996;24:235A.
- Nouri-Aria KT, Donaldson PT, Hegarty JE, et al. A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic hepatitis. Hepatology 1985;1: 235.
- O’Brien CJ, Vento S, Donaldson pT, et al. Cell-mediated immunity and suppressor T cell defects to liver-derived antigens in families of patients with autoimmune chronic hepatitis. Lancet 1986;1:350.
- Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis virus A as a trigger for autoimmune chronic hepatitis type i in susceptible individuals. Lancet 1991;337:1183.
- Vento S, Guella L, Mirandola F, et al. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 1995;346:608.
- Eddleston ALWF, Williams R. Inadequate antibody response to HBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet 1974;2:1543.
- Manns Mp, Griffin KJ, Sullivan KF, et al. LKM-1 autoantibodies recognize a short linear sequence in P450 IID6. J Clin Invest 1991;88:1370.
- Johnson PJ, McFarlane IG, Williams R. Azathioprine for long term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958.
- Crosignani A, Battezzati PM, Setchell KDR. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis. Hepatology 1991;13:339.